Rezolute is trading at $4.57 (-6.45%) amid a sharp intraday selloff, appearing to track broader biotech sector weakness rather than company-specific news.
- The decline follows a broader sector-wide downturn, with the biotech index falling 3.15% during the session.
- Shares are trading near the lower end of their recent range after finishing the previous session at $4.88.
- No specific catalysts, such as earnings, clinical trial data, or regulatory updates, have been identified for the move.